Open access
Clinical Benefit of Pembrolizumab in Lynch Syndrome‐Associated Advanced Ovarian Cancer With Germline MSH6 Variant: A Case Report
Tomomi Yokozawa
Sayako Nakagawa
Yukio Suzuki
Aya Tokinaga-Uchiyama
Katsuyuki Konnai
Hiroto Narimatsu
Yukihiko Hiroshima
Haruya Saji
Medicine
Abstract
This case highlights the importance of genetic evaluation during treatment in young patients with advanced ovarian cancer. Lynch syndrome caused by a germline MSH6 pathogenic variant was diagnosed during first‐line maintenance therapy, and pembrolizumab achieved a durable response in recurrent disease.